Pharmacokinetics and Safety of Rupatadine in Participants With Hepatic Impairment Compared to Control Participants.
NCT ID: NCT06736340
Last Updated: 2025-05-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
26 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-11-17
Study Completion Date
2025-04-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to assess the PK and safety of rupatadine (10 mg) and its active metabolites in participants with mild, moderate, or severe hepatic impairment compared to matched control participants with normal hepatic function. The study duration will be up to 38 days, including Screening, Baseline, Study Period, and EOS Visit assessments. Rupatadine 10 mg tablet will be administered as single dose.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants
NCT06708520
Renal Impairment
RECRUITING
PHASE1
Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria
NCT00199238
URTICARIA
TERMINATED
PHASE2
Chronic Urticaria - Long Term Assessment of Effects of Rupatadine
NCT02358265
Chronic Urticaria
TERMINATED
PHASE3
Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects
NCT00258141
Allergy
UNKNOWN
PHASE4
Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria
NCT01605487
Cold Contact Urticaria
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is an open-label, non-randomized, parallel group study comparing the PK after administration of a single 10 mg dose of rupatadine to participants with hepatic impairment with matched control participants with normal hepatic function (matched in terms of age, gender, and body weight).
For each participant, the study visits will consist of a screening period (Day -28 to Day -2), a baseline evaluation (Day -1), a single dose treatment period (Day 1), and an End of Study (EOS) Visit (Day 10). Additionally, from Day 2 to EOS participants will go back to the clinic every day for blood drawing.
Participants who meet the eligibility criteria at Screening and Baseline will be enrolled into the study.
All Baseline safety evaluation results must be reviewed prior to dosing. Participants will be domiciled at the clinic from Day -1 until 24 hours after dosing on Day 1 (Day 2).
On Day 1, participants will receive a single dose of rupatadine 10 mg after an overnight fast of 10 hours and will continue to fast for 4 hours postdose.
Participants will undergo sequential PK sampling over the following 192 hours along with other safety assessments as described in schedule of activities (SoA).
The participant groups will be consecutively enrolled into the study. Enrollment of participants with mild, moderate, and severe hepatic impairment will be staggered, so that dosing of participants with mild hepatic impairment will be started first. Dosing of the next group will be started only after evaluation of blood PK, safety and tolerability data until 72-hour postdose of at least 6 participants with hepatic impairment from the previous group and after the assessment of safety and tolerability results are judged to be satisfactory by Safety Committee.
An EOS assessment for each participant will occur at Day 10 after the administration of rupatadine.
The total study duration for each participant, including Screening, Baseline, Study Period, and EOS assessments, is approximately 38 days.
For each participant, the study visits will consist of a screening period (Day -28 to Day -2), a baseline evaluation (Day -1), a single dose treatment period (Day 1), and an End of Study (EOS) Visit (Day 10). Additionally, from Day 2 to EOS participants will go back to the clinic every day for blood drawing.
Participants who meet the eligibility criteria at Screening and Baseline will be enrolled into the study.
All Baseline safety evaluation results must be reviewed prior to dosing. Participants will be domiciled at the clinic from Day -1 until 24 hours after dosing on Day 1 (Day 2).
On Day 1, participants will receive a single dose of rupatadine 10 mg after an overnight fast of 10 hours and will continue to fast for 4 hours postdose.
Participants will undergo sequential PK sampling over the following 192 hours along with other safety assessments as described in schedule of activities (SoA).
The participant groups will be consecutively enrolled into the study. Enrollment of participants with mild, moderate, and severe hepatic impairment will be staggered, so that dosing of participants with mild hepatic impairment will be started first. Dosing of the next group will be started only after evaluation of blood PK, safety and tolerability data until 72-hour postdose of at least 6 participants with hepatic impairment from the previous group and after the assessment of safety and tolerability results are judged to be satisfactory by Safety Committee.
An EOS assessment for each participant will occur at Day 10 after the administration of rupatadine.
The total study duration for each participant, including Screening, Baseline, Study Period, and EOS assessments, is approximately 38 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hepatic Impairment
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
This is an open-label, non-randomized, parallel group study comparing the PK after administration of a single 10 mg dose of rupatadine to participants with hepatic impairment with matched control participants with normal hepatic function (matched in terms of age, gender, and body weight).
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hepatic imparement mild
Group Type
EXPERIMENTAL
Rupatadine
Intervention Type
DRUG
10mg tablets
Hepatic imparement moderate
Group Type
EXPERIMENTAL
Rupatadine
Intervention Type
DRUG
10mg tablets
Hepatic imparement severe
Group Type
EXPERIMENTAL
Rupatadine
Intervention Type
DRUG
10mg tablets
Hepatic normal functions
Group Type
EXPERIMENTAL
Rupatadine
Intervention Type
DRUG
10mg tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rupatadine
10mg tablets
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Pafinur
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Participants with normal hepatic function and participants with mild, moderate, or severe hepatic impairment who meet the following criteria will be considered eligible to participate in the clinical study:
1. Participant understands the study procedures and agrees to participate in the study by giving written informed consent prior to any study-mandated procedure.
2. Able to communicate well with the Investigator, to understand and comply with the study requirements.
3. Willing to comply with study restrictions stated in Section 5.3 (lifestyle considerations).
4. Male or female Caucasian subject, between 18 and 75 years (inclusive) of age.
5. Body mass index (BMI) is between 18 to 35 kg/m2 at Screening.
6. Women of childbearing potential (WoCBP) must have a negative serum pregnancy test at Screening, a negative urine pregnancy test on Day -1, and agree to consistently and correctly use (from 30 days prior to dosing, during the entire study, and for at least 30 days after dosing), a highly effective method of contraception (i.e., failure rate of \< 1%) (Section 10.4 \[Appendix 4\]). Such methods include:
\- Hormonal contraceptives: combined (estrogen- and progesterone-containing) contraception associated with inhibition of ovulation using oral, intravaginal, or transdermal route of administration.
Note: If a hormonal contraceptive is used, it must be initiated at least 30 days before dosing.
* Intrauterine device.
* Intrauterine hormone-releasing system.
* Bilateral tubal occlusion.
* Vasectomized partner, provided that the partner is the sole sexual partner and that the vasectomized partner has received medical assessment of the surgical success.
* Sexual abstinence, defined as refraining from heterosexual intercourse from 30 days prior to dosing up to at least 30 days after dosing, if this is the preferred and usual lifestyle of the subject. WoCBP must also agree not to donate ova from the time of informed consent until 30 days after dosing
7. Women of non-childbearing potential (WoNCBP), i.e., postmenopausal (defined as 12 consecutive months with no menses without an alternative medical cause, confirmed by a follicular stimulating hormone \[FSH\] test), with previous bilateral salpingectomy, bilateral salpingo-oophorectomy or hysterectomy, or with premature ovarian failure (confirmed by a specialist), XY genotype, Turner syndrome, uterine agenesis (Section 0 \[Appendix 4\]).
8. Male participants are infertile, vasectomized (who has received medical assessment of the surgical success) or must agree to abstain from, or to use a condom, during heterosexual intercourse with a woman of childbearing potential (Section 0 \[Appendix 4\]).
9. Male participants must agree not to donate sperm, from the time of informed consent until 30 days after dosing.
10. Participant agrees to refrain from consuming grapefruit juice, grapefruits, and grapefruitcontaining products from at least 7 days before the dose administration, and until the EOS Visit.
11. Able to tolerate venipuncture.
12. No clinically relevant abnormalities on rest vital signs.
13. No clinically relevant abnormalities on 12-lead ECG.
For participants with normal hepatic function the following criteria must be met in addition:
14. No clinically relevant diseases captured in medical history at Screening.
15. No clinically relevant abnormalities on physical examination and Screening and Baseline.
16. No clinically relevant abnormalities on clinical laboratory tests at Screening.
17. Weight within ±15% to his/her matched participant(s) enrolled in the study.
18. Biological sex matched to his/her matched participant(s) enrolled in the study.
19. Age within ±10 years to his/her matched participant(s) enrolled in the study.
20. Normal Blood Pressure (BP) measured on the same arm, after 5 min in the supine position at Screening and Baseline defined as:
* Systolic Blood Pressure (SBP) 90-140 mmHg, Diastolic Blood Pressure (DBP) 60-90 mmHg, and pulse rate 60-100 bpm (inclusive) for subjects \< 65 years of age.
* SBP 95-160 mmHg, DBP 65-95 mmHg, and pulse rate 60-100 bpm (inclusive) for subjects ≥ 65 years of age.
For participants with mild, moderate, or severe hepatic impairment the following criteria must be met in addition:
21. No clinically relevant abnormalities on clinical laboratory tests at Screening, except for those related to liver cirrhosis.
22. SBP 90-160 mmHg, DBP 60-95 mmHg, and pulse rate 60-100 bpm (inclusive), measured on the same arm, after 5 min in the supine position at Screening and Baseline.
23. Participant has a diagnosis of chronic (\> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic impairment, defined by Child Pugh Classification, with features of cirrhosis due to any etiology.
24. Child-Pugh scale score (see Section 4.2 for Child-Pugh Classification) from 5 to 6 (mild hepatic impairment), 7 to 9 (moderate hepatic impairment) or 10 to 15 (severe hepatic impairment) at the Screening Visit.
25. Stable concomitant medications for at least 21 days prior to dosing and up to the EOS visit.
1. Participant understands the study procedures and agrees to participate in the study by giving written informed consent prior to any study-mandated procedure.
2. Able to communicate well with the Investigator, to understand and comply with the study requirements.
3. Willing to comply with study restrictions stated in Section 5.3 (lifestyle considerations).
4. Male or female Caucasian subject, between 18 and 75 years (inclusive) of age.
5. Body mass index (BMI) is between 18 to 35 kg/m2 at Screening.
6. Women of childbearing potential (WoCBP) must have a negative serum pregnancy test at Screening, a negative urine pregnancy test on Day -1, and agree to consistently and correctly use (from 30 days prior to dosing, during the entire study, and for at least 30 days after dosing), a highly effective method of contraception (i.e., failure rate of \< 1%) (Section 10.4 \[Appendix 4\]). Such methods include:
\- Hormonal contraceptives: combined (estrogen- and progesterone-containing) contraception associated with inhibition of ovulation using oral, intravaginal, or transdermal route of administration.
Note: If a hormonal contraceptive is used, it must be initiated at least 30 days before dosing.
* Intrauterine device.
* Intrauterine hormone-releasing system.
* Bilateral tubal occlusion.
* Vasectomized partner, provided that the partner is the sole sexual partner and that the vasectomized partner has received medical assessment of the surgical success.
* Sexual abstinence, defined as refraining from heterosexual intercourse from 30 days prior to dosing up to at least 30 days after dosing, if this is the preferred and usual lifestyle of the subject. WoCBP must also agree not to donate ova from the time of informed consent until 30 days after dosing
7. Women of non-childbearing potential (WoNCBP), i.e., postmenopausal (defined as 12 consecutive months with no menses without an alternative medical cause, confirmed by a follicular stimulating hormone \[FSH\] test), with previous bilateral salpingectomy, bilateral salpingo-oophorectomy or hysterectomy, or with premature ovarian failure (confirmed by a specialist), XY genotype, Turner syndrome, uterine agenesis (Section 0 \[Appendix 4\]).
8. Male participants are infertile, vasectomized (who has received medical assessment of the surgical success) or must agree to abstain from, or to use a condom, during heterosexual intercourse with a woman of childbearing potential (Section 0 \[Appendix 4\]).
9. Male participants must agree not to donate sperm, from the time of informed consent until 30 days after dosing.
10. Participant agrees to refrain from consuming grapefruit juice, grapefruits, and grapefruitcontaining products from at least 7 days before the dose administration, and until the EOS Visit.
11. Able to tolerate venipuncture.
12. No clinically relevant abnormalities on rest vital signs.
13. No clinically relevant abnormalities on 12-lead ECG.
For participants with normal hepatic function the following criteria must be met in addition:
14. No clinically relevant diseases captured in medical history at Screening.
15. No clinically relevant abnormalities on physical examination and Screening and Baseline.
16. No clinically relevant abnormalities on clinical laboratory tests at Screening.
17. Weight within ±15% to his/her matched participant(s) enrolled in the study.
18. Biological sex matched to his/her matched participant(s) enrolled in the study.
19. Age within ±10 years to his/her matched participant(s) enrolled in the study.
20. Normal Blood Pressure (BP) measured on the same arm, after 5 min in the supine position at Screening and Baseline defined as:
* Systolic Blood Pressure (SBP) 90-140 mmHg, Diastolic Blood Pressure (DBP) 60-90 mmHg, and pulse rate 60-100 bpm (inclusive) for subjects \< 65 years of age.
* SBP 95-160 mmHg, DBP 65-95 mmHg, and pulse rate 60-100 bpm (inclusive) for subjects ≥ 65 years of age.
For participants with mild, moderate, or severe hepatic impairment the following criteria must be met in addition:
21. No clinically relevant abnormalities on clinical laboratory tests at Screening, except for those related to liver cirrhosis.
22. SBP 90-160 mmHg, DBP 60-95 mmHg, and pulse rate 60-100 bpm (inclusive), measured on the same arm, after 5 min in the supine position at Screening and Baseline.
23. Participant has a diagnosis of chronic (\> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic impairment, defined by Child Pugh Classification, with features of cirrhosis due to any etiology.
24. Child-Pugh scale score (see Section 4.2 for Child-Pugh Classification) from 5 to 6 (mild hepatic impairment), 7 to 9 (moderate hepatic impairment) or 10 to 15 (severe hepatic impairment) at the Screening Visit.
25. Stable concomitant medications for at least 21 days prior to dosing and up to the EOS visit.
Exclusion Criteria
Participants with normal hepatic function and participants with mild, moderate, or severe hepatic impairment who meet one or more of the following criteria will not be considered eligible to participate in the clinical study:
1. Pregnant or lactating women.
2. Participant is unlikely to comply with the protocol requirements, instructions and study related restrictions; e.g., uncooperative attitude, inability to return for the EOS Visit and improbability of completing the clinical study.
3. Any psychological, emotional problems, any disorders or resultant therapy that is likely to invalidate informed consent, or limit the ability of the participant to comply with the protocol requirements.
4. History of hypersensitivity to rupatadine, desloratadine or any of the excipients, or to medicinal products with similar chemical structures.
5. History of clinically significant lactose, galactose, or fructose intolerance.
6. Any clinically relevant acute or chronic disease which could jeopardize the safety of the participant or impact the validity of the study results.
7. History or presence of clinically significant angioedema.
8. Use of caffeine-containing beverages exceeding 800 mg per day (Section 5.3.2) at Screening.
9. Nicotine consumption (e.g., smoking, nicotine patch, nicotine chewing gum, or electronic cigarettes) from 48 h prior to Baseline (Day -1) until discharge from confinement (Day 2).
10. Positive test result for urine alcohol and drugs of abuse (amphetamines, benzodiazepines, cannabinoids, cocaine and opiates) at Screening and Baseline.
Note: Subjects receiving stable treatment of methadone and benzodiazepines will be allowed to be enrolled in the study even if the urine drug screen test is positive.
11. Veins unsuitable for intravenous puncture on either arm (e.g., veins that are difficult to locate, access, or puncture, veins with a tendency to rupture during or after puncture).
12. Participation in another clinical trial with an experimental drug within 2 months or 5 halflives (whichever is longer) before the Screening or in more than 2 clinical studies within 1 year prior to Screening.
13. Positive results at Screening from either the hepatitis B or C serology based on hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody (Ig M and total antihepatitis B core antibody), and hepatitis C virus antibody (HCV) markers, except for vaccinated subjects or subjects with past resolved hepatitis.
Note: If HCV antibody is present, HCV RNA analysis should be performed, and the result must be "not detected".
14. History of heart, liver or kidney transplantation.
15. Active malignant neoplastic disease or carcinoma (including leukemia, lymphoma, malignant melanoma), or myeloproliferative disease, regardless of the time since treatment.
16. Use of any of the following within 2 weeks prior to investigational medicinal product (IMP) administration or 5 half-lives, whichever is longer:
1. Enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism (e.g., azole antifungals \[ketoconazole, itraconazole, fluconazole, posaconazole, voriconazole\], macrolide antibiotics \[erythromycin, clarithromycin\], diltiazem, human immunodeficiency virus (HIV) protease inhibitors, nefazodone, rifampicin, phenytoin, dexamethasone, troglitazone, and barbiturates)
2. CYP3A4 substrates with a narrow therapeutic index (e.g., ciclosporin, tacrolimus, sirolimus, everolimus, cisapride)
3. Desloratadine
17. Clinically significant abnormalities on ECG repolarization (QTcF \> 450 ms in males and \> 470 ms in females) at Screening.
18. Loss of 250 mL or more blood within 3 months prior to screening.
For participants with normal hepatic function, the additional criteria must not be met:
History or clinical evidence of alcohol or drug abuse within the 3 years prior to Screening.
19. Estimated glomerular filtration rate (eGFR) \< 90 mL/min for subjects aged ≤ 45 years, and \<70 mL/min for subjects aged \> 45 years, as determined by the Cockcroft-Gault equation, at Screening.
20. Intake of any prescribed medication (including vaccines) including over-the-counter (OTC) medication (including herbal and dietary supplements such as St John's Wort, homeopathic preparations, vitamins and minerals) that could affect the outcome of the study as judged by the Investigator, within 14 days before the administration of the IMP or less than 5 times the half-life of that medication, whichever is longer (excluding contraceptives and hormone replacement therapy).
For participants with mild, moderate or severe renal impairment, the additional criteria must not be met:
21. Severe portal hypertension or surgical porto-systemic shunts, including transjugular intrahepatic portosystemic shunt
22. eGFR \< 60 mL/min as determined by the Cockcroft-Gault equation, at Screening.
23. History or clinical evidence of infection with hepatitis B and/or hepatitis C within the preceding 6 months.
1. Pregnant or lactating women.
2. Participant is unlikely to comply with the protocol requirements, instructions and study related restrictions; e.g., uncooperative attitude, inability to return for the EOS Visit and improbability of completing the clinical study.
3. Any psychological, emotional problems, any disorders or resultant therapy that is likely to invalidate informed consent, or limit the ability of the participant to comply with the protocol requirements.
4. History of hypersensitivity to rupatadine, desloratadine or any of the excipients, or to medicinal products with similar chemical structures.
5. History of clinically significant lactose, galactose, or fructose intolerance.
6. Any clinically relevant acute or chronic disease which could jeopardize the safety of the participant or impact the validity of the study results.
7. History or presence of clinically significant angioedema.
8. Use of caffeine-containing beverages exceeding 800 mg per day (Section 5.3.2) at Screening.
9. Nicotine consumption (e.g., smoking, nicotine patch, nicotine chewing gum, or electronic cigarettes) from 48 h prior to Baseline (Day -1) until discharge from confinement (Day 2).
10. Positive test result for urine alcohol and drugs of abuse (amphetamines, benzodiazepines, cannabinoids, cocaine and opiates) at Screening and Baseline.
Note: Subjects receiving stable treatment of methadone and benzodiazepines will be allowed to be enrolled in the study even if the urine drug screen test is positive.
11. Veins unsuitable for intravenous puncture on either arm (e.g., veins that are difficult to locate, access, or puncture, veins with a tendency to rupture during or after puncture).
12. Participation in another clinical trial with an experimental drug within 2 months or 5 halflives (whichever is longer) before the Screening or in more than 2 clinical studies within 1 year prior to Screening.
13. Positive results at Screening from either the hepatitis B or C serology based on hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody (Ig M and total antihepatitis B core antibody), and hepatitis C virus antibody (HCV) markers, except for vaccinated subjects or subjects with past resolved hepatitis.
Note: If HCV antibody is present, HCV RNA analysis should be performed, and the result must be "not detected".
14. History of heart, liver or kidney transplantation.
15. Active malignant neoplastic disease or carcinoma (including leukemia, lymphoma, malignant melanoma), or myeloproliferative disease, regardless of the time since treatment.
16. Use of any of the following within 2 weeks prior to investigational medicinal product (IMP) administration or 5 half-lives, whichever is longer:
1. Enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism (e.g., azole antifungals \[ketoconazole, itraconazole, fluconazole, posaconazole, voriconazole\], macrolide antibiotics \[erythromycin, clarithromycin\], diltiazem, human immunodeficiency virus (HIV) protease inhibitors, nefazodone, rifampicin, phenytoin, dexamethasone, troglitazone, and barbiturates)
2. CYP3A4 substrates with a narrow therapeutic index (e.g., ciclosporin, tacrolimus, sirolimus, everolimus, cisapride)
3. Desloratadine
17. Clinically significant abnormalities on ECG repolarization (QTcF \> 450 ms in males and \> 470 ms in females) at Screening.
18. Loss of 250 mL or more blood within 3 months prior to screening.
For participants with normal hepatic function, the additional criteria must not be met:
History or clinical evidence of alcohol or drug abuse within the 3 years prior to Screening.
19. Estimated glomerular filtration rate (eGFR) \< 90 mL/min for subjects aged ≤ 45 years, and \<70 mL/min for subjects aged \> 45 years, as determined by the Cockcroft-Gault equation, at Screening.
20. Intake of any prescribed medication (including vaccines) including over-the-counter (OTC) medication (including herbal and dietary supplements such as St John's Wort, homeopathic preparations, vitamins and minerals) that could affect the outcome of the study as judged by the Investigator, within 14 days before the administration of the IMP or less than 5 times the half-life of that medication, whichever is longer (excluding contraceptives and hormone replacement therapy).
For participants with mild, moderate or severe renal impairment, the additional criteria must not be met:
21. Severe portal hypertension or surgical porto-systemic shunts, including transjugular intrahepatic portosystemic shunt
22. eGFR \< 60 mL/min as determined by the Cockcroft-Gault equation, at Screening.
23. History or clinical evidence of infection with hepatitis B and/or hepatitis C within the preceding 6 months.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Noucor Health S.A.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Serafim Guimarães, MD
Role: PRINCIPAL_INVESTIGATOR
Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
Rosa Maria Príncipe, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Pedro Hispano
Joana Cochicho, MD
Role: PRINCIPAL_INVESTIGATOR
Centro Hospitalar de Vila Nova de Gaia/Espinho
Dolores Ochoa Mazarro, MD
Role: PRINCIPAL_INVESTIGATOR
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Ana Maria Aldea Perona, MD
Role: PRINCIPAL_INVESTIGATOR
Municipal Institute Of Medical Investigation
Germán Soriano Pastor, MD
Role: PRINCIPAL_INVESTIGATOR
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Alberto Borobia Pérez, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario La Paz
Antonio Portolés Pérez, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Clinico San Carlos
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BlueClinical Phase I
Porto, Porto District, Portugal
Site Status
Centro Hospitalar De Vila Nova De Gaia Espinho
Gaia, , Portugal
Site Status
Hospital Pedro Hispano
Matosinhos Municipality, , Portugal
Site Status
Municipal Institute Of Medical Investigation
Barcelona, , Spain
Site Status
Hospital Universitario De La Princesa
Madrid, , Spain
Site Status
Hospital Clinico San Carlos
Madrid, , Spain
Site Status
Hospital Universitario La Paz
Madrid, , Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Portugal
Spain
References
Explore related publications, articles, or registry entries linked to this study.
Billah MM, Chapman RW, Egan RW, Gilchrest H, Piwinski JJ, Sherwood J, Siegel MI, West RE Jr, Kreutner W. Sch 37370: a potent, orally active, dual antagonist of platelet-activating factor and histamine. J Pharmacol Exp Ther. 1990 Mar;252(3):1090-6.
Reference Type
BACKGROUND
Eiser NM, Mills J, Snashall PD, Guz A. The role of histamine receptors in asthma. Clin Sci (Lond). 1981 Apr;60(4):363-70. doi: 10.1042/cs0600363.
Reference Type
BACKGROUND
Cuss FM, Dixon CM, Barnes PJ. Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet. 1986 Jul 26;2(8500):189-92. doi: 10.1016/s0140-6736(86)92489-x.
Reference Type
BACKGROUND
Henocq E, Vargaftig BB. Accumulation of eosinophils in response to intracutaneous PAF-acether and allergens in man. Lancet. 1986 Jun 14;1(8494):1378-9. doi: 10.1016/s0140-6736(86)91683-1. No abstract available.
Reference Type
BACKGROUND
Piwinski JJ, Wong JK, Green MJ, Ganguly AK, Billah MM, West RE Jr, Kreutner W. Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines. J Med Chem. 1991 Jan;34(1):457-61. doi: 10.1021/jm00105a069. No abstract available.
Reference Type
BACKGROUND
Prescott SM, Zimmerman GA, McIntyre TM. The production of platelet-activating factor by cultured human endothelial cells: Regulation and function. In Platelet-activating factor and related lipid mediators. Snyder F, Ed. New York: Plenum Press, 1987: 323-340.
Reference Type
BACKGROUND
Katiyar S, Prakash S. Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis. Prim Care Respir J. 2009 Jun;18(2):57-68. doi: 10.3132/pcrj.2008.00043.
Reference Type
BACKGROUND
Mullol J, Bousquet J, Bachert C, Canonica WG, Gimenez-Arnau A, Kowalski ML, Marti-Guadano E, Maurer M, Picado C, Scadding G, Van Cauwenberge P. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008 Apr;63 Suppl 87:5-28. doi: 10.1111/j.1398-9995.2008.01640.x.
Reference Type
BACKGROUND
Queralt M, Brazis P, Merlos M, de Mora F, Puigdemont A. In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm Res. 2000 Jul;49(7):355-60. doi: 10.1007/PL00000216.
Reference Type
BACKGROUND
Merlos M, Ramis I, Balsa D, Queralt M, Brazís P, Puigdemont A. Inhibitory effect of rupatadine on TNF-a release from human monocytes and mast cell lineHMC-1. J.Allergy Clin. Immunol. 2000 105(Suppl.1): S62.
Reference Type
BACKGROUND
Bartra J, Valero AL, del Cuvillo A, Davila I, Jauregui I, Montoro J, Mullol J, Sastre J. Interactions of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006;16 Suppl 1:29-36. No abstract available.
Reference Type
BACKGROUND
del Cuvillo A, Mullol J, Bartra J, Davila I, Jauregui I, Montoro J, Sastre J, Valero AL. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006;16 Suppl 1:3-12. No abstract available.
Reference Type
BACKGROUND
Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;(182):335-60. doi: 10.1007/978-3-540-74806-9_16.
Reference Type
BACKGROUND
Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother. 2006 Oct;7(14):1989-2001. doi: 10.1517/14656566.7.14.1989.
Reference Type
BACKGROUND
Izquierdo I, Merlos M, Garcia-Rafanell J. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc). 2003 Jun;39(6):451-68. doi: 10.1358/dot.2003.39.6.799450.
Reference Type
BACKGROUND
Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs. 2007;67(3):457-74. doi: 10.2165/00003495-200767030-00008.
Reference Type
BACKGROUND
European Medicines Agency. Committee for Medicinal Products for Human Use Guidance: Guideline on the Investigation of Drug Interactions. 21 June 2012.
Reference Type
BACKGROUND
Rupatadine Investigator's Brochure, dated 21 Sep 2021
Reference Type
BACKGROUND
Palatini P, De Martin S. Pharmacokinetic drug interactions in liver disease: An update. World J Gastroenterol. 2016 Jan 21;22(3):1260-78. doi: 10.3748/wjg.v22.i3.1260.
Reference Type
BACKGROUND
Food and Drug Administration Guidance: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. May 2003.
Reference Type
BACKGROUND
European Medicines Agency. Committee for Medicinal Products for Human Use Guidance: Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Hepatic Function. February 2005
Reference Type
BACKGROUND
FDA Guidance: Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency-Guidance for Industry, Investigators, and Institutional Review Boards: August 2021
Reference Type
BACKGROUND
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646-9. doi: 10.1002/bjs.1800600817. No abstract available.
Reference Type
BACKGROUND
DMID ALCOAC Checklist V2.0 29 January 2020.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://www.medicines.org.uk/emc/product/2501/smpc#gref
Summary of Product Characteristics (SmPC) for rupatadine
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DC08RUP/1/21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria
NCT00199251
TERMINATED
PHASE3
Study on Mastocytosis for Rupatadine Treatment
NCT01481909
COMPLETED
PHASE2/PHASE3
Study on the Effect and Mechanism of Lupatadine Fumarate in the Treatment of Allergic Rhinitis
NCT06709092
RECRUITING
NA
Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function
NCT02775981
COMPLETED
PHASE1
This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines
NCT03926611
COMPLETED
PHASE2
A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
NCT07091357
RECRUITING
PHASE2
Study of Stapokibart Injection in Patients With Allergic Rhinitis
NCT06525597
RECRUITING
PHASE2
A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)
NCT01957202
COMPLETED
PHASE2
A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis
NCT01949051
COMPLETED
PHASE2
Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy
NCT02661854
UNKNOWN
PHASE2
Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis
NCT00524836
COMPLETED
PHASE3
To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis
NCT00525278
COMPLETED
PHASE3
Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units
NCT00718744
COMPLETED
PHASE2
Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP).
NCT00917488
COMPLETED
PHASE2
A Study of RO4989991 in Patients With Allergic Rhinitis
NCT01152619
COMPLETED
PHASE1
Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge
NCT01260753
COMPLETED
PHASE2
A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine
NCT01962467
COMPLETED
PHASE1
Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants
NCT03969849
COMPLETED
PHASE1
A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts
NCT01012752
UNKNOWN
PHASE3
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of HRS-3095 Oral Administration in Healthy Subjects, as Well as the Effect of HRS-3095 on CYP3A4 Metabolic Enzymes
NCT07230418
RECRUITING
PHASE1
Allergic Rhinitis Combination Pharmacotherapy Efficacy Study
NCT04601324
WITHDRAWN
PHASE4
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
NCT07220811
RECRUITING
PHASE2
723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover
NCT00972504
COMPLETED
PHASE2
PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
NCT01438463
COMPLETED
PHASE2
Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients
NCT00973453
COMPLETED
PHASE2